1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Swedish Biotech Developing Stem Cell Therapies From Amniotic Fluid

Newly Listed Amniotics Will Target Niche Indications

 
• By Sten Stovall

Swedish biotech Amniotics is developing a broad pipeline of unique stem cell therapeutics based on technology that is broadly applicable to major disease markets which should eventually draw the attention of big pharma players, its CEO tells Scrip.

Mesenchymal Stem Cells are collected from Term Amniotic Fluid • Source: Alamy

Sweden-based Amniotics AB  is in the early stages of developing a unique stem cell-based pipeline using amniotic fluid sourced from caesarean section births – an approach that is ethically sound and offers secure supply given the rising trend globally of C-section delivery, the biotech’s CEO has told Scrip.

Amniotics’ technology is based on collecting mesenchymal stem cells (MSC) from amniotic fluid, followed by a patent protected enhancement of the MSCs into several kinds of tissue or organ specific pharmaceutical products

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By Kevin Grogan

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.

Lilly Builds Obesity Momentum With New SURMOUNT Data Besting Novo Nordisk

 
• By Alaric DeArment

The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.

Which Firms Are Most Exposed To Prasad’s Possible Accelerated Approvals Clampdown?

 
• By Andrew McConaghie

Vaccine and accelerated approvals are expected to face greater scrutiny under new CBER leader Vinay Prasad, but he has promised “no light switch change” to policy, giving some reassurance to companies whose share prices have been battered.